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Highlights 
 Of the study sample, 28% (533/1876) had reported a skin and soft tissue infections (SSTI) 
in the past year. 
 People who inject drugs (PWID) with the high IE-OST uptake had lower odds of having 
had a SSTI infection.   
 Nevertheless, 24% of those PWID with high IE-OST uptake still experienced a SSTI. 
 
ABSTRACT  
Background: Bacterial skin and soft tissue infections (SSTIs) are a health issue for people 
who inject drugs (PWID). There is a lack of evidence on the associations between harm 
reduction (HR) uptake and SSTIs. This paper examines the associations between the uptake 
of injecting equipment (IE) and opiate substitution treatment (OST) on SSTIs among PWID, 
Page 2 of 24 
 
and the injecting behaviours associated with having had an SSTI. This is the first large-scale, 
national study to examine the association between IE uptake and SSTIs. 
Methods: A cross-sectional, voluntary and anonymous survey was undertaken with PWID 
recruited from pharmacies/agencies providing IE across mainland Scotland during 2013-
2014. Participants were asked: if they had an SSTI within the past year; about their uptake of 
HR within the past 6 months (including needle/syringes (N/S), paraphernalia and OST); and 
about their frequency of injecting, sharing of IE and re-use of own N/S. Data from 1876 
PWID who had reported injecting within the past 6 months were analysed. 
Findings: In multivariate logistic regression, those with high combined IE-OST uptake 
(adjusted odds ratio [AOR] 0.614, 95% CI 0.458-0.823, p = 0.001) and medium combined 
IE-OST uptake (AOR 0.725, 95% CI 0.546–0.962, p = 0.026) had lower odds of having had 
an SSTI compared to those with low combined IE-OST uptake.  
Conclusions: IE and OST uptake may reduce the level of SSTIs among PWID, suggesting 
increasing combined uptake maybe beneficial. Nevertheless, a sizeable proportion of PWID 
with high HR uptake experienced SSTIs, suggesting the importance of other interventions. 
 
Keywords: people who inject drugs; skin and soft tissue infection; bacterial infection; 
injecting equipment; opiate substitution treatment; harm reduction 
 
1. Introduction  
 Bacterial skin and soft tissue infections (SSTIs) are a health issue for people who 
inject drugs (PWID). Infections are caused by a number of bacteria, such as those from the 
injectors’ own skin, and those present in contaminated drugs, cutting agents or injecting 
paraphernalia (Gordon and Lowy, 2005). Although most of these infections are localised, 
mild and superficial, they can result in serious morbidity and mortality when associated with 
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systemic symptoms such as fever, rapid heartbeat or low blood pressure, or with a co-
morbidity, sepsis syndrome or a life-threatening infection, such as necrotizing fasciitis 
(Dryden, 2009). Harm reduction (HR), such as the provision of sterile injecting equipment 
(IE) or opiate substitution treatment (OST), may be important to help prevent the potential 
onset of serious infection (Hope, 2010).  
 The most common forms of injection site SSTIs are abscesses or cellulitis (Fink et al., 
2011; Hope, 2010). Prevalence studies from Europe, North America and Australia have 
shown that 21% to 32% of PWID had a current abscess (Binswanger et al., 2000; Morrison et 
al., 1997; Saeland et al., 2014); 7% to 36% had an abscess or open wound within the past 
year (Dwyer et al., 2009; Hope et al., 2010; Maloney, 2010; Phillips and Stein, 2010; Public 
Health England et al., 2014). Re-use or sharing of unsterile needles and syringes (N/S) has 
been shown to be associated with increased SSTI prevalence (Hope et al., 2014b; Hope et al., 
2008; Lloyd-Smith et al., 2008; Maloney, 2010), as has the re-use and sharing of injecting 
paraphernalia, in particular, filters and flush water (Hope et al., 2010). More frequent 
injecting is also associated with SSTIs (Hope et al., 2014b; Hope et al., 2010; Phillips and 
Stein, 2010): repeated injections damage the skin and tissues providing a focus for infection 
(Pieper and Hopper, 2005). Limited research exists examining the association between HR, 
such as IE provision and OST, and SSTIs among PWID. The total number of clean N/S 
distributed from a needle exchange (NE) and the opening of a NE were shown to be 
associated with reduced SSTI prevalence (Bhattacharya et al., 2006; Hart et al., 1989; 
Tomolillo et al., 2007). None of these small-scale single site studies showed the level of 
injection equipment (IE) uptake needed per individual for use sterile IE for every injection. 
Those who took OST in the past but not currently had higher odds of having had an SSTI in 
the past year (Hope et al., 2008). Others have demonstrated that combined high uptake of N/S 
and OST was associated with reduced incidence of HCV among PWIDs in Scotland 
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(Palmateer et al., 2014); and OST and IE provision services have been shown to reduce self-
reported injecting risk behaviours, such as the borrowing, lending, re-use of N/S or 
paraphernalia, and injecting frequency (MacArthur et al., 2014); and IE provision (IEP) and 
OST are associated with reduced HIV infection (Degenhardt et al., 2010; Palmateer et al., 
2010). Notably, no study has examined the associations between the uptake of sterile IE, or 
the combined effect of IE and OST uptake, on SSTIs. This paper will be unique by analysing 
data from a national survey of PWID conducted in Scotland. The paper also examines 
injecting behaviours associated with having had an SSTI. 
2. Materials and methods  
2.1 Data source 
 Data used for this paper was gathered in 2013-2014 as part of the Needle Exchange 
Surveillance Initiative (NESI) Scotland study. NESI is a cross sectional, voluntary, and 
anonymous survey, which has been on-going since 2008 (University of the West of Scotland 
et al., 2015). Between February 2013 and February 2014, participants were recruited from 
106 pharmacies and 28 agencies providing a fixed site, mobile or outreach IEP service across 
Scotland’s eleven mainland NHS Health Boards. Healthcare for Scotland is devolved to 
regional Health Boards. Trained interviewers asked eligible participants to participate in a 15-
minute face-to-face questionnaire. Those eligible had injected drugs at least once in the past 
and had not already participated in the current data collection sweep. The questionnaire 
included questions on drug use history, injecting risk behaviours and harms, IE and OST 
uptake and participant demographics. All participants provided informed consent, were 
provided with a £5 shopping-voucher, and interviews were conducted in a private room. 
Ethics approval was obtained from the West of Scotland NHS Research Ethics Committee.  
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2.2 Measures  
2.2.1 Outcome measure 
 This was measured using the question ‘In the last year, have you had a swelling 
containing pus (abscess), a sore or open wound at an injection site?’  
2.2.2 Intervention measures 
 HR interventions considered were IE uptake and OST, that is, methadone. These 
measures which were derived from the questionnaire have been used in previous work 
(Palmateer et al., 2014) and included uptake of: i.) N/S, ii.) paraphernalia, iii.) combined IE 
(N/S and paraphernalia) , iv.) OST, and v.) combined IE and OST. 
 N/S uptake was derived by dividing the self-reported number of N/S obtained in the 
last six months by the self-reported number of injections in the last six months. This was 
categorised into high and low uptake. The threshold for high uptake (200%+, at least twice as 
many N/S as injections) has been used in previous work, where it was chosen on the basis of 
sensitivity analyses (Palmateer et al., 2014). Paraphernalia uptake was derived by combining 
filter and spoon uptake. Those who reported high uptake (200%+) of both spoons and filters 
were classified as having high paraphernalia uptake, with the remaining falling into low 
category. A combined variable, called IE uptake, was derived where those with high uptake 
(200%+) on both N/S and paraphernalia were categorised as high and the remaining were 
categorised as low. OST uptake was defined as ‘never been on OST’, ‘currently on OST at 
the time of the study’ or ‘on OST in the past but not currently’. A final combined uptake 
variable was derived by combining IE and OST uptake, with categories low, medium and 
high. In order to derive this combined variable, those who had ‘never been on OST’ or ‘on 
OST in the past but not currently’ were combined to represent not currently on OST. The 
‘Low combined IE-OST’ uptake category included those with low IE uptake and were not 
currently on OST; ‘medium combined IE-OST’ uptake included those with either low IE 
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uptake and were currently on OST, or had high IE uptake but were not currently on OST; 
‘high combined IE-OST’ uptake included those who had high IE uptake and were currently 
on OST.  
2.2.3 Injecting behaviours 
 Injecting behaviours included frequency of injecting, sharing IE and re-use of one’s 
own N/S. These were self-reported and related to the past 6 months. Frequency of injection 
was categorised as daily or more, or less than daily. Sharing IE (including N/S, spoons and 
filters) was categorised as yes/no. Re-using one’s own N/S was measured as yes/no to record 
if the N/S had been re-used more than once.  
2.3 Statistical Analysis 
 Logistic regression was used to calculate the odds of self-reported SSTI associated 
with i.) uptake of the HR interventions and ii.) injecting behaviours. Associations between 
other variables and SSTI were also explored using Pearson’s χ2test (Table 1). The 
confounders selected for inclusion in the multivariate logistic regression were those found to 
be statistically significant (p<0.05) using the bivariate analysis in Table 1 and those 
previously found to be associated with SSTI prevalence. The potential confounders included 
Health Board area, time since onset of injecting, injection of more than one drug (‘poly-drug 
use’), gender, and homeless in the past six months. Poly-drug use was included, rather than 
stimulant use, to incorporate the number of emerging new psychoactive substances (NPS) 
injectors in the sample – such as ‘Burst’. For time since onset of injecting, ‘<5 years’ and ‘5-
10 years’ was collapsed to ‘<10 years’ to give a reference group with a larger sample size. 
Injecting risk behaviour and injecting frequency variables were not considered for the 
regression models examining HR interventions and SSTI because they are on the causal 
pathway, but injecting frequency was included as a confounder in the regression model for 
SSTI and sharing IE, and re-use of N/S. Multivariate regression was generated by forward 
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step-wise analysis and was statistically significant at p<0.05 (Table 2 and Table 3). Analyses 
were undertaken with SPSS version 22. 
3. Results 
 Of the 2463 participants, 119 duplicate records from individuals who had participated 
more than once were excluded. Of the remaining 2344 respondents, those who had not 
injected within the past 6 months (n=402), those who exclusively injected bodybuilding drugs 
(n=58), as this group were less likely to have had an SSTI, and those with missing injecting 
status (n=9) were excluded. The remaining 1876 participants were analysed. 
 Of the sample, 28% (533/1876) had reported an SSTI in the past year, 30% 
(555/1866) were female, 52% (984/1875) were aged 35 years or more and 38% (714/1874) 
had been injecting for less than 10 years. The majority were currently prescribed methadone 
(71%, 1326/1875), 78% (1472/1874) had injected heroin only in the past six months and 37% 
(530/1436) had been homeless in the past six months, and 66% (1240/1865) were ever in-
prisoned. Table 1 shows that those who had an SSTI within the past year were more likely to 
be from an East of Scotland Health Board area, injected for 20 years or more, or were poly-
drug injectors. 
 Table 2 presents the associations between the uptake of HR interventions in the 
previous 6 months and having had an SSTI within the past year. The multivariable analysis 
was controlled for Health Board area, years of injecting, poly-drug use, gender and homeless 
in the past six months. Multivariable analysis demonstrates that those with high N/S (Model 
1), high paraphernalia (Model 2), high IE (Model 3) uptake all had lower odds of having had 
an SSTI relative to those with low uptake. N/S and paraphernalia uptake was highly 
correlated (CRAMERS V = 0.79, p=0.000). Those individuals who had never been on OST 
or were currently on OST had lower odds of having had an SSTI than those previously on 
OST (Model 4). Further analysis shows that those who had never been on OST were more 
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likely to be the early-stage injectors - 72% (117/162) of those who had never been on OST 
had been injecting for less than 10 years compared to 35% (467/1325) of those currently on 
OST and 33% (129/386) of past users of OST (χ2=91.04, p=0.000, n=1853), and they were on 
average 3 years younger (mean = 33.61, sd = 9.39) (F(2, 1871) = 15.59, p=0.00). However, a 
sizeable number of those never on OST injected daily (57%, 92/162).  
 Model 5 examines the combined IE-OST uptake. Those individuals with the highest 
or complete level of uptake (high IE uptake and currently on OST), and those with medium 
uptake (either low IE and on OST, or high IE and no OST) had lower odds of having had an 
SSTI compared to those with low uptake (low IE uptake and no OST). Across all five 
models, those with high combined uptake had marginally the lowest odds of having had an 
SSTI.  
 Table 3 shows that those who injected daily or more often, shared any IE or re-used 
N/S had higher odds of having had an SSTI in the past year. Notably, 21% of those who did 
not inject daily or more, or re-use N/S and 25% who did not share any IE still experienced an 
SSTI.  
4. Discussion  
 Our study shows that 28% of PWID had a self-reported SSTI within the past year and 
those PWID with high combined IE-OST uptake or medium combined IE-OST uptake had 
lower odds of having had an SSTI compared to those with low combined IE-OST uptake. 
Nevertheless, 24% of PWID with high HR uptake still experienced an SSTI within the past 
year. 
 Our prevalence of 28% is within the range of prevalence reported internationally 
where 7% to 36% of PWID had an abscess or open wound within the past year (Dwyer et al., 
2009; Hope et al., 2010; Maloney, 2010; Phillips and Stein, 2010). However, it is difficult to 
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make direct comparisons with other studies due to the heterogeneity of PWID definitions, 
recruitment strategies and sampling. 
 Little is known about the impact of HR interventions on SSTIs. During the late 1980s 
NE services were piloted in Scotland (Stimson et al., 1988) however a need to action an 
expansion and improvement of IEP services across all NHS Boards and the development of 
guidelines was identified as part of a national Hepatitis C Action Plan (Phase II: 2008-2011) 
(The Scottish Government, 2008, 2010). Scotland now has a comprehensive HR programme 
which provides unlimited free access to IE (including N/S, spoons, filters, acidifiers, water 
for injection and pre-injection swabs) as advocated in national IEP guidelines, and OST, 
mainly via pharmacies and drug treatment agencies (The Scottish Government, 2010). The 
IEP guidelines focused on the prevention of HCV but they recognised that provision of sterile 
IE alongside safer injecting advice (washing hands with soap and water before injecting, and 
the correct IE usage) may also impact on SSTIs.  
 Our findings suggest that Scotland’s HR provision of IE and OST impacts on SSTIs 
but it is noteworthy that a sizeable proportion of PWID with high HR uptake still experienced 
SSTIs. High IE uptake relative to low IE uptake within the past six months was associated 
with lower odds of having had an SSTI within the past year, as was being currently on OST 
relative to having been on OST in the past. Approximately a third of PWID with low IE or 
OST uptake had an SSTI within the past year, compared to approximately a quarter of PWID 
with high IE or OST uptake. Notably, the combined effect of high IE and-OST had 
marginally the lowest odds of having had an SSTI. Consequently, increasing the provision of 
clean IE coupled with OST may be a beneficial HR intervention for SSTIs. The mismatch in 
timeframes for IE uptake (six months) and presence/absence of an SSTI (one year) occurred 
because of the nature of the data available; SSTI over a one year period was collected to 
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allow comparability with other prevalence studies. This mismatch may tend to under-estimate 
the association being measured, and therefore our finding is conservative. 
 Further analysis showed that those who shared any IE, re-used N/S or injected daily 
or more had higher odds of having had an SSTI in the past year. Others have also shown that 
sharing or re-using N/S is associated with increased SSTI prevalence (Hope et al., 2014a; 
Hope et al., 2008; Lloyd-Smith et al., 2008; Murphy et al., 2001), as is the re-use and sharing 
of injecting paraphernalia (Hope et al., 2010). Earlier work using previous sweeps of NESI 
has established that high IE uptake and being on OST reduced the odds of sharing N/S, 
spoons or filters, and of injecting daily or more respectively (Palmateer et al., 2014).  
 The uptake of at least twice as much IE as needed, that is high uptake (200%+), may 
be protective against SSTIs. Firstly, injectors may have difficulty accessing veins (Hope et 
al., 2016) and may need several needles to achieve one successful injection. Secondly, 
plentiful supplies cover times of poor access to IEP services, for example, Sundays or 
evenings. An ample supply of sterile IE may negate the need to share or re-use needles that 
may have become contaminated with bacteria. Bacterial contamination of injecting 
equipment such as syringes, cookers (Tuazon et al., 1974) and filters (Caflisch et al., 1999; 
Scott, 2008) has been observed. Equally, it cannot be discounted that participants may have 
over-estimated their IE uptake.  
 Interestingly, the odds of having had an SSTI were higher among those who were 
previously (but not currently) on OST; this is consistent with Hope et al.’s (2008) findings, 
and mirrors the pattern of association between OST and HCV infection (Allen et al., 2012). 
The nature of this association is unclear and further research is needed. It may be suggestive 
of a number of factors including: those no longer on OST were those who have failed in 
treatment, for whatever reason, and have relapsed into injecting representing a high-risk 
group by possibly engaging in risker practices which contributed to a higher SSTI occurrence 
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(e.g., more frequent injecting, experiencing more missed hits, less cleaning of injections sites) 
or there is less contact with HR information/advice from drug treatment services or the 
factors that explain why they were no longer engaging with OST also explain the higher SSTI 
occurrence. Also, those PWID who had never been on OST had the lowest odds of having 
had an SSTI – these individuals were perhaps those with less tissue damage because of 
shorter injecting careers or non-progression to groin injecting. However, a sizeable 
proportion of those who were never on OST were frequent injectors and it may be that, in 
time, this group will experience more SSTIs if interventions or safer injecting practices are 
not taken up. 
 Due to the cross-sectional nature of the data collection, we cannot infer causality and 
need to be mindful of alternative explanations for the associations between IE/OST uptake 
and SSTIs – that is, high IE uptake, per se, may not be the main reason for the lower SSTI 
prevalence but may be a marker for other factors associated with the outcome. For example, 
it is possible that those who have high IE uptake were a low-risk group who engaged in other 
safer practices (such as hand washing, injection site cleaning or injecting site rotation not 
included in the model) that reduced SSTI risk. Similarly, high IE uptake may reflect PWID 
who use HR services more frequently and are thus more likely to receive education/support 
about injecting practice and hygiene.  
 Equally, there are many potential causes of SSTI among PWID other than sharing/re-
use of IE, including environmental contamination from public injecting, groin or hand 
injecting, poor personal hygiene, contaminated drugs, damaged skin/tissue due to missed hits 
or overuse of citric acid/Vitamin C. These other causes may explain why a quarter of PWIDs 
had experienced an SSTI within the past year despite high HR uptake. Additionally, 
approximately a fifth of those who did not inject daily or had not re-used their N/S had an 
SSTI and a quarter of those who had not shared any piece of IE had an SSTI. In other words, 
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IEP and OST cannot mitigate against all risks of bacterial infection and other forms of HR are 
equally, if not more, important such as: promoting and facilitating hand washing, swabbing 
injection sites, injection site rotation, preventing transition to injecting, vein and wound care 
and advising PWID to seek timely healthcare during, for example, outbreaks of serious 
infections arising from spore-forming bacteria. However, the effectiveness of behavioural 
change interventions can be undermined by situational and social contexts of injecting 
(Moore, 2004). Being in a hurry or impatient to inject, being in withdrawal plus not having 
clean supplies and not thinking about skin cleaning are barriers to self-initiated skin cleaning 
(Bonar and Rosenberg, 2014) ; also PWID keep used filters to extract residual drugs (Taylor 
A. et al., 2004) and these filters may harbour bacteria (Scott, 2008). Consequently, 
notwithstanding the high uptake of HR, health services will be needed to respond to SSTIs 
(Hope, 2010).  
 IEP services may provide more effective HR for SSTIs if combined with other 
services such as drug consumption rooms (DCRs) or nurse-led wound clinics (Bassetti and 
Battegay, 2004; Hope, 2010). Care for SSTIs can be delivered via specialised clinics set up in 
DCRs (Fast et al., 2008; Lloyd-Smith et al., 2010), hospitals (Harris and Young, 2002), IEP 
sites (Grau et al., 2002; Nesbitt, 2015) including mobile outreach IEP services (Robinowitz et 
al., 2014) and via charitable organisations (Finnie and Nicolson, 2002). Guidelines advocate 
that specialist IEP programmes should offer comprehensive HR packages including advice on 
safer injecting practices, assessment of injection site infections and SSTI treatment/referral 
(NICE, 2014).  
 Non-intervention variables found to be associated with increased odds of having had 
an SSTI included: residing in an East of Scotland Health Board area, longer injecting 
histories and poly-drug use. Further work is needed to explain the regional differences – these 
may in part reflect regional differences in the drugs taken – for example, SSTI problems are 
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emerging among NPS injectors, specifically Lothian in the East of Scotland which has 
experienced an increase in injecting of ethylphenidate (Lafferty et al., 2016) or contamination 
of local drug supplies. Analysis (not shown) stratifying injecting history as “< five years” 
versus “≥ five years” was not statistically significant suggesting that within our sample, it is 
those with longer injecting histories (such as 20 years plus) rather than new injectors that 
were experiencing more SSTIs. Interventions targeted to the above groups may help reduce 
SSTI harms. The similar SSTI prevalence between those “ever been in prison” and “never in 
prison” may be explained by the low levels of in-prison injecting within Scottish prisons 
because of the range of HR policies, particularly the increased OST availability (Taylor et al., 
2013). This suggests that most SSTIs were acquired within the community rather than in-
prison. 
4.1 Limitations 
 There are a number of limitations. Firstly, it cannot be discounted that selection bias 
occurred. The survey sampled PWID who are in contact with IEP services, which may result 
in an under-estimation of SSTI prevalence among high-risk injectors not in contact with such 
services. On the other hand, if these IEP services offered wound care clinics there may have 
been an over-representation of PWID with SSTI who were seeking advice/treatment. 
Secondly, we were unable to ask questions about other HR practices pertinent to SSTIs, such 
as hand washing, swabbing, injecting site rotation or other risk factors such as skin/muscle 
popping, quantity of citric acid used, filter re-use, needle licking or healthcare seeking 
behaviours for SSTIs. Thirdly, the uptake of IE was measured over a six-month timeframe 
whilst the prevalence of SSTIs was measured over the past year. This occurred because of the 
nature of the data available, and may have lessened the association between the outcome and 
exposure variables. Fourthly, the presence/absence of an SSTI was determined by self-report. 
We cannot discount that for some participants an SSTI may have been forgotten, not deemed 
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worthy of mention or another skin problem was reported as an SSTI. However, Morrison et 
al. (1997) found that PWID self-report of current injecting related harm, including abscesses, 
conferred with medical examination, and suggests accurate self-reporting. 
4.2 Conclusions and future research 
 Even though high IE-OST uptake was associated with the lowest odds ratio for having 
had an SSTI in the past year, a sizeable proportion of PWID with high IE-OST uptake still 
experienced SSTIs. This suggests that IE and OST are needed as part of a wider HR package 
for SSTIs. HR services which provide wound/SSTI clinics delivered via DCRs or NE maybe 
needed. In addition, an understanding of SSTIs and HR in relation to PWID lives and 
injecting experiences is needed to inform the development of services to reduce, and support 
PWID with, SSTIs. 
 
Authors Disclosures 
Role of funding source 
NESI study was funded by the Scottish Government. The work for this paper was supported 
by Health Protection Scotland, the Scottish Government and the University of the West of 
Scotland.  The funders had no role in study design, data collection, analysis, decision to 
publish, or preparation of the manuscript. 
 
Contributors 
AT, AM, SH, NP and DG designed the survey, with KR contributing to the question on 
SSTIs.  AM, TK and AT led on the implementation of the survey.  KD undertook data 
analysis with support from SH and NP. KD wrote the drafts of the manuscript. All authors 
critically reviewed and approved the final manuscript. 
 
Page 15 of 24 
 
Conflict of interest statement 
'Conflicts of interest: none'. 
 
Acknowledgements 
We are grateful to those who participated in the NESI survey, undertook the data collection, 
and the organisations who allowed access to their services. We would also like to thank the 
Scottish Government for funding this study. 
  
Page 16 of 24 
 
REFERENCES 
Allen, E., Palmateer, N., Hutchinson, S., Cameron, S., Goldberg, D., Taylor, A., 2012. 
Association between harm reduction intervention uptake and recent hepatitis C infection 
among people who inject drugs attending sites that provide sterile injecting equipment in 
Scotland. Int. J. Drug Policy 23, 346- 352. 
Bassetti, S., Battegay, M., 2004. Staphylococcus aureus infections in injection drug users: 
Risk factors and prevention strategies. Infection 32, 163-169. 
Bhattacharya, M.K., Naik, T.N., Palit, A., Bhattacharya, S.K., 2006. Impact of a harm-
reduction programme on soft tissue infections among injecting drug users of Kolkata, 
India. J. Health, Pop. Nutr. 24, 121-122. 
Binswanger, I.A., Kral, A.H., Bluthenthal, R.N., Rybold, D.J., Edlin, B.R., 2000. High 
prevalence of abscesses and cellulitis among community-recruited injection drug users in 
San Francisco. Clin. Infect. Dis. 30, 579-581. 
Bonar, E.E., Rosenberg, H., 2014. Injection drug users' perceived barriers to using self-
initiated harm reduction strategies. Addict. Res. Theory 22, 271-278. 
Caflisch, C., Wang, J., Zbinden, R., 1999. The role of syringe filters in harm reduction among 
injection drug users. Am. J. Public Health 89, 1252-1254. 
Degenhardt, L., Mathers, B., Vickerman, P., Rhodes, T., Latkin, C., Hickman, M., 2010. HIV 
in people who use drugs 2 Prevention of HIV infection for people who inject drugs: why 
individual, structural, and combination approaches are needed. Lancet 376, 285-301. 
Dryden, M.S., 2009. Skin and soft tissue infection: microbiology and epidemiology. 
International Journal of Antimicrobial Agents 34, Suppl-7. 
Dwyer, R., Topp, L., Maher, L., Power, R., Hellard, M., Walsh, N., Jauncey, M., Conroy, A., 
Lewis, J., Aitken, C., 2009. Prevalences and correlates of non-viral injecting-related 
Page 17 of 24 
 
injuries and diseases in a convenience sample of Australian injecting drug users. Drug and 
Alcohol Dependence 100, 9-16. 
Fast, D., Small, W., Wood, E., Kerr, T., 2008. The perspectives of injection drug users 
regarding safer injecting education delivered through a supervised injecting facility. Harm 
Reduction Journal 5. 
Fink, B., Landthaler, M., Hafner, C., 2011. Skin alterations due to illegal drug abuse. JDDG: 
Journal der Deutschen Dermatologischen Gesellschaft 9, 633-639. 
Finnie, A., Nicolson, P., 2002. Injecting drug use: developing a drop-in wound care clinic. 
British Journal of Nursing 11 (Supplement). 
Gordon, R., Lowy, F., 2005. Bacterial infections in drug users. The New England Journal of 
Medicine 353, 1945-1954. 
Grau, L.E., Arevalo, S., Catchpool, C., Heimer, R., Diffusion Benefit Syringe Exchange, 
2002. Expanding harm reduction services through a wound and abscess clinic. Am. J. 
Public Health 92, 1915-1917. 
Harris, H.W., Young, D.M., 2002. Care of injection drug users with soft tissue infections in 
San Francisco, California. Arch. Surg. 137, 1217-1222. 
Hart, G.J., Carvell, A.L.M., Woodward, N., Johnson, A.M., Williams, P., Parry, J.V., 1989. 
Evaluation of needle exchange in central London: Behaviour change and anti-HIV status 
over one year. AIDS 3, 261-266. 
Hope, V., 2010. Neglected infections, real harms: A global scoping of injection-related 
bacterial infections and responses. In: Cook, C. (Ed.), The Global State of Harm Reduction 
2010 - Key issues for broadening the response. International Harm Reduction Association, 
London. pp. 89-95. 
Page 18 of 24 
 
Hope, V., Cullen, K.J., Croxford, S., Parry, J.V., Ncube, F., 2014a. Factors associated with 
the use of cleaned needles and syringes among people who inject drugs in the UK: Who 
should we target to minimise the risks? Int. J. Drug Policy 25, 924-927. 
Hope, V., Hickman, M., Parry, J.V., Ncube, F., 2014b. Factors associated with recent 
symptoms of an injection site infection or injury among people who inject drugs in three 
English cities. Int. J. Drug Policy 25, 303-307. 
Hope, V., Kimber, J., Vickerman, P., Hickman, M., Ncube, F., 2008. Frequency, factors and 
costs associated with injection site infections: findings from a national multi-site survey of 
injecting drug users in England. BMC Infect. Dis. 8. 
Hope, V., Marongiu, A., Parry, J.V., Ncube, F., 2010. The extent of injection site infection in 
injecting drug users: findings from a national surveillance study. Epidemiol. Infect. 138, 
1510-1518. 
Hope, V.D., Parry, J.V., Ncube, F., Hickman, M., 2016. Not in the vein: ‘Missed hits’, 
subcutaneous and intramuscular injections and associated harms among people who inject 
psychoactive drugs in Bristol, United Kingdom. Int. J. Drug Policy 28, 83-90. 
Lafferty, C., Smith, L., Coull, A., Shanley, J., 2016. The experience of an increase in the 
injection of ethylphenidate in Lothian April 2014-March 2015. Scott. Med. J. 
Lloyd-Smith, E., Wood, E., Zhang, R., Tyndall, M.W., Montaner, J.S., Kerr, T., 2008. Risk 
factors for developing a cutaneous injection-related infection among injection drug users: 
A cohort study. BMC Public Health 8, 405. 
Lloyd-Smith, E., Wood, E., Zhang, R., Tyndall, M.W., Sheps, S., Montaner, J.S.G., Kerr, T., 
2010. Determinants of hospitalization for a cutaneous injection-related infection among 
injection drug users: A cohort study. BMC Public Health 10, 327. 
MacArthur, G.J., van Velzen, E., Palmateer, N., Kimber, J., Pharris, A., Hope, V., Taylor, A., 
Roy, K., Aspinall, E., Goldberg, D., Rhodes, T., Hedrich, D., Salminen, M., Hickman, M., 
Page 19 of 24 
 
Hutchinson, S.J., 2014. Interventions to prevent HIV and Hepatitis C in people who inject 
drugs: A review of reviews to assess evidence of effectiveness. Int. J. Drug Policy 25, 34-
52. 
Maloney, S., 2010. What are the risk factors for soft tissue abscess development among 
injecting drug users? Nurs. Times 106, 21-24. 
Moore, D., 2004. Governing street-based injecting drug users: a critique of heroin overdose 
prevention in Australia. Soc. Sci. Med. 59, 1547-1557. 
Morrison, A., Elliott, L., Gruer, L., 1997. Injecting-related harm and treatment-seeking 
behaviour among injecting drug users. Addiction 92, 1349-1352. 
Murphy, E.L., DeVita, D., Liu, H., Vittinghoff, E., Leung, P., Ciccarone, D.H., Edlin, B.R., 
2001. Risk factors for skin and soft-tissue abscesses among injection drug users: A case-
control study. Clin. Infect. Dis. 33, 35-40. 
Nesbitt, H., 2015. From needle exchange to sexual health and beyond. Nurs. Times 111, 16-
18. 
NICE, 2014. Needle And Syringe Programmes. p. 56. 
Palmateer, N., Kimber, J., Hickman, M., Hutchinson, S., Rhodes, T., Goldberg, D., 2010. 
Evidence for the effectiveness of sterile injecting equipment provision in preventing 
hepatitis C and human immunodeficiency virus transmission among injecting drug users: 
A review of reviews. Addiction 105, 844-859. 
Palmateer, N.E., Taylor, A., Goldberg, D.J., Munro, A., Aitken, C., Shepherd, S.J., Mc 
Allister, G., Gunson, R., Hutchinson, S.J., 2014. Rapid decline in HCV incidence among 
people who inject drugs assoicated with national scale-up in coverage of a combination of 
harm reduction interventions. PLOS ONE 9, 1-14. 
Phillips, K.T., Stein, M.D., 2010. Risk practices associated with bacterial infections among 
injection drug users in Denver, Colorado. Am. J. Drug Alcohol Abuse 36, 92-97. 
Page 20 of 24 
 
Pieper, B., Hopper, J.A., 2005. Injection drug use and wound care. Nurs. Clinics 40, 349-363. 
Public Health England, Health Protection Scotland, Public Health Wales, Public Health 
Agency Northern Ireland, 2014. Shooting up: Infections among people who inject drugs in 
the United Kingdom 2013. London. 
Robinowitz, N., Smith, M.E., Serio-Chapman, C., Chaulk, P., Johnson, K.E., 2014. Wounds 
on wheels: Implementing a specialized wound clinic within an established syringe 
exchange program in Baltimore, Maryland. Am. J. Public Health 104, 2057-2059. 
Saeland, M., Wandel, M., Böhmer, T., Haugen, M., 2014. Abscess infections and 
malnutrition - a cross-sectional study of polydrug addicts in Oslo, Norway. Scand. J. Clin. 
Lab. Invest. 74, 322-328. 
Scott, J., 2008. Safety, Risks And Outcomes From The Use Of Injecting Paraphernalia. 
University of Bath. 
Stimson, G.V., Alldritt, L., Dolan, K., Donoghoe, M., 1988. Syringe exchange schemes for 
drug-users in England and Scotland. Br. Med. J. 296, 1717-1719. 
Taylor, A., Munro, A., Allen, E., Dunleavy, K., Cameron, S., Miller, L., Hickman, M., 2013. 
Low incidence of hepatitis C virus among prisoners in Scotland. Addiction 108, 1296-
1304. 
Taylor A., Fleming A., Rutherford J., Goldberg, D., 2004. Examining the Injecting Practices 
of Injecting Drug Users in Scotland. Scottish Executive, Edinburgh. p. 54. 
The Scottish Government, 2008. Hepatitis C Action Plan for Scotland Phase II: May 2008 - 
March 2011. Edinburgh. p. 49. 
The Scottish Government, 2010. Guidelines For Services Providing Injecting Equipment. 
Best Practice Recommendations For Commissioners And Injecting Equipment Provision 
(IEP) services in Scotland. The Scottish Government, Edinburgh. p. 64. 
Page 21 of 24 
 
Tomolillo, C.M., Crothers, L.J., Aberson, C.L., 2007. The damage done: A study of injection 
drug use, injection related abscesses and needle exchange regulation. Subst. Use Misuse 
42, 1603-1611. 
Tuazon, C.U., Hill, R., Sheagren, J.N., 1974. Microbiologic study of street heroin and 
injection paraphernalia. J. Infect. Dis. 129, 327-329. 
University of the West of Scotland, Health Protection Scotland, Glasgow Caledonian 
University, West of Scotland Specialist Virology Centre, 2015. Needle Exchange 
Surveillance Initiative (NESI): Prevalence of HCV and injecting risk behaviours among 
people who inject drugs (PWID) attending injecting equipment provision services (IEPs) 
in Scotland, 2008/2009 - 2013/2014. University of the West of Scotland, Paisley. p. 40. 
  
Page 22 of 24 
 
Table 1. Demographics of PWID1 who had a SSTI2 in the past year 
 
Demographic N Had a SSTI 2 
     n  %     
P-value 3 
Male 
Female 
1306 
553 
374 (29)  
156 (28) 
0.852 
Ever homeless 
  No 
  Yes 
 
430 
1435 
 
118 (27) 
414 (29) 
 
0.570 
Homeless in past 6 months  
  No 
  Yes 
 
1333 
529 
 
388 (29)       
143 (27) 
 
0.371 
Ever in prison                           
  No  
  Yes 
 
622 
1238 
 
175 (28) 
356 (29) 
 
0.780 
Age (years) 
  <= 25  
  26-30 
  31-35 
  >35 
 
149 
277 
462 
980 
 
  40 (27)               
  75 (27)           
116 (25)         
302 (31)         
0.129 
Excessive alcohol 4                          
  No 
  Yes 
 
1388 
475 
 
385 (28) 
145 (30) 
 
0.245 
Health Board Areas 5 
  West & Central  
  East  
  North 
 
1109 
540 
220 
 
290 (26) 
188 (35) 
  55 (25) 
 
0.001 
Time since onset injecting (yrs.) 
  < 10 
  10-14 
  15-19 
  20+ 
 
711 
465 
327 
364 
 
208 (29)         
118 (25)         
  79  (24)         
128 (35)         
 
0.004 
Poly-drug injection6                       
  No 
  Yes 
 
1567 
300 
 
399 (26) 
133 (44)  
 
0.000 
1. Defined as those who injected in past 6 months and excludes those who solely injected bodybuilding drugs 
2. Defined as self-reported swelling containing pus (abscess), a sore or an open wound at an injection site. 
3. Pearson chi square test 
4. Defined as > 14units/week for women and >21units per week for men 
5. West & Central:  Greater Glasgow & Clyde, Lanarkshire, Ayrshire & Annan, Dumfries & Galloway, Forth Valley 
East: Lothian, Fife, Tayside, Borders 
North: Highlands and Grampian 
6. Defined as use of more than one drug type in past 6 months (where drug type is Opiate, Stimulant or Other including 
Legal Highs) 
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Table 2. Univariable and multivariable models of associations between uptake of HR and SSTIs within the past year among current injectors 
 
Model Intervention Had a SSTI 
____________ 
n/N           (%)  
Univariable 
__________________________
OR             (95% CI)         P-
value 
Multivariable 1 
___________________________ 
AOR         (95% CI)          P-value 
1 N/S Uptake 2, 3 
  Low (<200% uptake) 
  High (≥ 200% uptake) 
 
258/767   (34) 
270/1085 (25) 
 
1 
0.654 (0.533-0.801)    0.000  
 
1 
0.719 (0.581-0.888)     0.002 
2 Paraphernalia  Uptake 4 
  Low (<200% uptake) 
  High (≥ 200% uptake) 
 
258/792   (33) 
270/1060 (25) 
 
1 
0.707 (0.577-0.867) 0.001  
 
1 
0.771 (0.625-0.950)     0.015  
4 IE Uptake 5  
  Low (<200% uptake) 
  High (≥ 200% uptake) 
 
280/869   (32) 
246/979   (25) 
 
1 
0.706 (0.576-0.865)    0.001  
 
1 
0.775 (0.628-0.956)     0.017  
3 OST                                                        
  Past 
  Never  
  Current 
 
139/380   (36) 
  42/162   (26) 
352/1320 (27) 
 
1 
0.622 (0.413-0.936)    0.023  
0.646 (0.508-0.822)    0.000  
 
1 
0.593 (0.386-0.910) 0.017 
0.672 (0.524-0.862) 0.002 
5 Combined IE & OST 6                                      
  Low  
  Medium 
  High 
 
117/316   (37) 
225/777   ( 28) 
184/754   (24) 
 
1 
0.693 (0.526-0.914)    0.022  
0.549 (0.414-0.728)    0.000 
 
1 
0.732 (0.551-0.973)    0.032  
0.622 (0.463-0.834)    0.002 
1. All multivariable models adjusted for Poly-drug use (No, Yes), Time since onset of injecting(<10, 10-14, 15-19, 20+ year), Region (West & Central Scotland, East Scotland, North), 
Gender (Male, Female), Homeless past 6 months (No, Yes) 
2. Includes new, unused NS obtained from others 
3. Adjusts for number of months injected 
4. Paraphernalia includes spoons and filters 
5. IE includes N/S and paraphernalia.  
6. Low = Low IE, no OST; Medium = Low IE + OST, or High IE + no OST; High = High IE + OST (where No OST = never and in the past; OST = currently prescribed)  
OR= Odds Ratio, AOR= Adjusted odds Ratio, CI = Confidence Interval, N/S = needle/syringe, IE = injecting equipment, OST = opiate substitution treatment 
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Table 3. Univariable and multivariable models of association between frequency of injecting, sharing any IE, re-using N/S and SSTIs among current injectors 
 
Model Injecting behaviour Had a SSTI  
n/N (%) 
Univariable 
_______________________ 
OR             (95% CI)      P-
value 
Multivariable 1, 2  
_________________________ 
AOR         (95% CI)          P-
value 
1  Injecting frequency 
1 to 3 times a month 
About once a week 
2 to 6 times a week 
Once a day 
2 to 3 times a day 
4 or more times a day 
 
  95/511    (19) 
  35/158    (22) 
  80/327    (25) 
  64/240    (27) 
185/455    (41) 
  72/175    (41) 
 
1 
1.246 (0.805-1.928)    0.323 
1.418 (1.013-1.986)    0.042 
1.592 (1.108-2.288)    0.012 
3.000 (2.243-4.014)    0.000 
3.061 (2.105-4.452)    0.000 
 
1 
1.242 (0.798-1.932) 0.337 
1.267 (0.897-1.789) 0.179 
1.490 (1.029-2.158) 0.035 
2.703 (2.003-3.648) 0.000 
2.641 (1.791-3.892) 0.000 
2 Shared any IE in the 
last 6 months    
  No 
  Yes 
 
 
348/1363 (25) 
173/465    (37) 
 
 
1 
1.728   (1.381-2.162)   0.000 
 
 
1 
1.479 (1.164-1.878) 0.000  
3 Re-used own N/S in 
the last 6 months3    
  No  
  Yes 
 
 
188/875   (21) 
345/992   (35) 
 
 
1 
1.949   (1.583-2.398)   0.000 
 
 
1 
1.506 (1.199-1.893) 0.000 
1. Model 1 adjusted for Poly-drug use (No, Yes), Health Board Area (West & Central, East,  North), Time since onset of injecting(<10, 10-14, 15-19, 20+ years), Gender (Male, Female), 
Homeless past 6 months (No, Yes) 
2. Model 2 & 3 adjusted for Injecting Frequency (1 to 3 times a month, About once a week, 2 to 6 times a week, Once a day, 2 to 3 times a day, 4 or more times a day), Poly-drug use (No, 
Yes), Health Board Area (West & Central, East,  North), Time since onset of injecting(<10, 10-14, 15-19, 20+ years), Gender (Male, Female), Homeless past 6 months (No, Yes) 
3. Defined as re-used own N/S more than once before discarding it   
OR= Odds Ratio, AOR= Adjusted odds Ratio, CI = Confidence Interval, N/S = needle/syringe, IE = injecting equipment, OST = opiate substitution treatment 
